ClinicalTrials.gg
CompletedNCT02613520Updated Oct 15, 2018

Safety and Immunogenicity in Age De-Escalation of PfSPZ Vaccine in Tanzanian Adults, Children, and Infants

A Phase 1 interventional study of PfSPZ Vaccine and Normal Saline in Malaria, sponsored by Sanaria Inc.. Completed at 1 site in Tanzania. Open to participants aged 6 Months to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-10-15.

Sponsored by Sanaria Inc. · Phase 1, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
105
Allocation
Randomized
Ages
6 Months to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies in Malaria by Sanaria Inc. — 3 open to participants now, 3 under way, none of them phase 3. Malaria · Sanaria Inc..

Enrollment
8th of 27
105 · median 67
Started
2015
with 1 other
Phase 1
20 of 27
1 open now
Registered
12th of 27
by date

Among the 27 studies in Malaria by Sanaria Inc., this one is the 8th largest by enrollment, is one of 2 that started in 2015, is one of 20 in phase 1, and was the 12th registered.

Malaria

1,185 studies on the registry are indexed under Malaria; 80 are open to participants now.

Browse Malaria studies →

Open to participants now

3 of the 27 studies in Malaria by Sanaria Inc. are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 52 Malaria studies recruiting now, 15 (29%) set no upper age limit and 34 (65%) stop at 75 or younger; 38 take children under 18; 32 take healthy volunteers.

This study: 6 Months to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Malaria by Sanaria Inc., or all of them as a file.
02

Study summary

The present trial will evaluate safety and tolerability as well as the vaccine-induced humoral and cellular immune responses in healthy Tanzanian adults, adolescents, children, and infants who receive doses of 1.8x10\^6, 9.0x10\^5, 4.5x10\^5 or 2.7x10\^5 PfSPZ of PfSPZ Vaccine by direct venous inoculation (DVI),compared with control groups receiving normal saline (NS) placebo by DVI. In addition, as an exploratory objective, controlled human malaria infection (CHMI) will be used to assess efficacy in adults three weeks following immunization.

Read the detailed description

This is a single center trial to assess the safety, tolerability and immunogenicity of PfSPZ Vaccine administered by direct venous inoculation (DVI) to healthy Tanzanian adults, adolescents, and children and infants. 105 healthy male and female; adults, adolescents, children and infant volunteers, aged from 6 months to 45 years, who live in the Bagamoyo Township will be enrolled based on pre-defined inclusion and exclusion criteria implemented according to international ethical standards.

The safety and tolerability of PfSPZ Vaccine administered as three doses of either 9.0x10\^5 PfSPZ or 1.8x10\^6 PfSPZ to healthy Tanzanian adults, adolescents, and children 6 years of age or older; and three doses of 4.5x10\^5 PfSPZ or 9.0x10\^5 PfSPZ to healthy Tanzanian children 1 to 5 years of age and infants 6 to 11 months of age, in each case compared to NS controls, will be evaluated. In addition, as an exploratory objective, controlled human malaria infection (CHMI) will be used to assess efficacy in adults three weeks following immunization.

Study Design: This is a single center trial with ten groups (Groups 1a/b: ages 18-45; Group 2a/b: ages 11-17; Group 3a/b: ages 6-10; Group 4a/b: ages 1-5; and Group 5b/c: ages 6months-11 months) each with 6 subjects receiving PfSPZ Vaccine and 3 subjects receiving NS and an eleventh smaller group (Group 5a: ages 6months-11months) with 3 subjects receiving PfSPZ Vaccine; two of these groups (Group 1a/b) contain adult volunteers and will have infectivity controls (CHMI 1 and 2) each having 3 subjects, after the vaccination phase of the study. The adult volunteers will undergo CHMI 3 weeks after the last immunization.

For the first immunization, two volunteers (out of six) in Group 1a will receive 9x10\^5 of PfSPZ Vaccine by DVI as sentinels, to demonstrate safety and tolerability. At the same time, one (out of three) corresponding control volunteers will receive NS, in order to maintain blinding. Approximately 24 hours later, provided criteria for calling an ad hoc SMC meeting are not met, the remaining four volunteers in Group 1a will also receive a 9x10\^5 PfSPZ dose of the vaccine and the remaining two placebo recipients will receive NS.

After review of at least +14 days post vaccination safety data for Group 1a by the SMC, if there are no significant safety concerns, two volunteers (out of six) in Group 1b will receive 1.8x10\^6 PfSPZ, and two volunteers (out of six) in each of the Groups 2a and 3a will receive 9x10\^5 PfSPZ, of the PfSPZ Vaccine, to demonstrate safety and tolerability, and each of these sentinel groups will be joined by one corresponding NS control in order to maintain blinding. Approximately 24 hours later, provided criteria for calling an ad hoc SMC meeting are not met, the remaining four volunteers in Group 1b will receive 1.8x10\^6 PfSPZ and the remaining four volunteers in each of Groups 2a and 3a will receive 9x10\^5 PfSPZ of the PfSPZ Vaccine, and the remaining placebo recipients will receive NS.

After review of at least +14 days post vaccination safety data for Groups 1b, 2a and 3a by the SMC, if there are no significant safety concerns, two volunteers (out of six) in each of the Groups 2b and 3b will receive 1.8x10\^6 PfSPZ, those in Group 4a will receive 4.5x10\^5 PfSPZ and all 3 volunteers in Group 5a will receive 2.7x10\^5 PfSPZ of PfSPZ Vaccine, to demonstrate safety and tolerability, and each of the sentinel groups (two volunteers from Groups 2b, 3b and 4a) will be joined by one NS control in order to maintain blinding. Approximately 24 hours later, provided criteria for calling an ad hoc SMC meeting are not met, the remaining four volunteers in Groups 2b, 3b and 4a will receive their appropriate dose of PfSPZ Vaccine (1.8x10\^6 PfSPZ, 1.8x10\^6 PfSPZ, and 4.5x10\^5 PfSPZ, respectively), and the placebo recipients will receive NS.

Escalation from the small group of infants, (Group 5a, n=3) receiving a single dose of 2.7x10\^5 PfSPZ, to the full group (Group 5b, n=6) receiving three doses of 4.5x10\^5 PfSPZ, will proceed without SMC review if criteria for calling an ad hoc SMC meeting are not met. However, if the criteria are met, an ad hoc SMC meeting will be called to review the data, and dose escalation to 4.5x10\^5 PfSPZ will be postponed until the recommendations of the SMC are available. The interval between the 2.7x10\^5 PfSPZ small group and the 4.5x10\^5 PfSPZ larger group will be a minimum of three days.

After review of at least +14 days post vaccination, safety data for Groups 2b, 3b, 4a, 5a and 5b by the SMC, if there are no significant safety concerns, two volunteers (out of six) in each of the Groups 4b and 5c will receive 9x10\^5 PfSPZ, to demonstrate safety and tolerability. At the same time, one (out of three) corresponding control volunteers will receive NS, in order to maintain blinding. Approximately 24 hours later, provided criteria for calling an ad hoc SMC meeting are not met, the remaining four volunteers in Group 4b and 5c will receive 9x10\^5 PfSPZ dose of the vaccine, and the placebo recipients will receive NS.

03

Conditions studied

  • Malaria

Keywords

  • PfSPZ Vaccine
  • Plasmodium falciparum
04

Who can participate

Ages eligible
6 Months to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy males and females, based on clinical and laboratory findings
  • From the age 6 months to 45 years
  • Adults with a (BMI) 18 to 30 Kg/m2; or adolescents, children and infants with Z-score of the selected indicator ([weight-for-height], [(height and BMI) for age]) category within ±2SD as detailed in protocol
  • Long term (at least one year) or permanent residence in the Bagamoyo town or nearby villages
  • Agreement to release medical information and to inform the study doctor concerning for participation in the study
  • Willingness to be attended to by a study clinician and take all necessary medications prescribed during study period
  • Agreement to provide contact information of a third party household member or close friend to study team
  • Availability through mobile phone 24 hours during the entire study period
  • Agreement not to participate in another clinical trial during the study period
  • Agreement not to donate blood during the study period
  • Able and willing to complete the study visit schedule over the study follow up period, including the hospitalizations required for protocol compliance
  • Willingness to undergo , (HBV) and (HCV) tests
  • Volunteer (subjects 18 years of age and older) and parent or guardian signing (for subjects \<18 years of age) is able to demonstrate their understanding of the study by responding correctly to 10 out of 10 true/false statements (in a maximum of two attempts for those who failed to respond correctly to all true/false statements in the first attempt)
  • Signed written informed consent, in accordance with local practice, provided by adult volunteers, parents or legal representatives and relevant assent for children participants as applicable
  • Free from malaria parasitaemia by blood smear at enrolment
  • Free from helminth infections at enrolment, or diagnosed with helminthes and treated appropriately to eliminate infestation
  • Female volunteers aged 9 years and above must be non-pregnant (as demonstrated by a negative serum pregnancy test), and provide consent / assent of their willingness to take protocol-defined measures not to become pregnant during the study and safety follow-up period

Exclusion criteria

Exclusion Criteria:

  • Previous receipt of an malaria vaccine or drug in the last 5 years
  • Participation in any other clinical study involving investigational medicinal products within 30 days prior to the onset of the study or during the study period
  • History of arrhythmias or prolonged -interval or other cardiac disease, or abnormalities in (ECG) at screening
  • Positive family history in a 1st or 2nd degree relative for cardiac disease at age \<50 years old
  • A history of psychiatric disease
  • Suffering from any chronic illness including; diabetes mellitus, cancer or /AIDS
  • Any confirmed or suspected or immune-deficient condition, including asplenia
  • History of drug or alcohol abuse interfering with normal social function
  • The use of chronic immunosuppressive drugs or other immune modifying drugs within three months of study onset (inhaled and topical are allowed) and during the study period
  • Any clinically significant deviation from the normal range in biochemistry or hematology blood tests or in urine analysis
  • Positive HIV, virus or virus tests
  • Volunteers who are suspected as having clinically active TB by history or physical examination with positive QuantiFERON-TB Gold Test In-Tube assay
  • Symptoms, physical signs and laboratory values suggestive of systemic disorders including renal, hepatic, blood, cardiovascular, pulmonary, skin, immunodeficiency, psychiatric, and other conditions which could interfere with the interpretation of the study results or compromise the health of the volunteers
  • Any medical, social condition, or occupational reason that, in the judgment of the investigator, is a to protocol participation or impairs the volunteer's ability to give , increases the risk to the volunteer because of participation in the study, affect the ability of the volunteer to participate in the study or impair interpretation of the study data
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
105 participants (actual)

Study arms

  • Experimental
    Group 1a (PfSPZ Vaccine)

    18- 45 years; n=6; 3 doses of 9 x 10\^5 PfSPZ Vaccine given 8 weeks apart. Volunteers will undergo CHMI with PfSPZ Challenge 3 weeks after the last immunization.

    Biological: PfSPZ Vaccine · Biological: PfSPZ Challenge (for CHMI)

  • Placebo comparator
    Group 1a (normal saline)

    18- 45 years; n=3; 3 doses of normal saline given 8 weeks apart. Volunteers will undergo CHMI with PfSPZ Challenge 3 weeks after the last immunization.

    Other: Normal Saline · Biological: PfSPZ Challenge (for CHMI)

  • Other
    Group 1a (CHMI controls)

    18- 45 years; n=6; volunteers will not receive any intervention, but will serve only as infectivity controls; 3 volunteers each, for CHMI 1 and for CHMI 2 in Group 1a. Volunteers will be injected with PfSPZ Challenge (for CHMI).

    Biological: PfSPZ Challenge (for CHMI)

  • Experimental
    Group 1b (PfSPZ Vaccine)

    18- 45 years; n=6; 3 doses of 1.8 x 10\^6 PfSPZ Vaccine given 8 weeks apart. Volunteers will undergo CHMI with PfSPZ Challenge 3 weeks after the last immunization.

    Biological: PfSPZ Vaccine · Biological: PfSPZ Challenge (for CHMI)

  • Placebo comparator
    Group 1b (normal saline)

    18- 45 years; n=3; 3 doses of normal saline given 8 weeks apart. Volunteers will undergo CHMI with PfSPZ Challenge 3 weeks after the last immunization.

    Other: Normal Saline · Biological: PfSPZ Challenge (for CHMI)

  • Other
    Group 1b (CHMI controls)

    18- 45 years; n=6; volunteers will not receive any intervention, but will serve only as infectivity controls; 3 volunteers each, for CHMI 1 and for CHMI 2 in Group 1b. Volunteers will be injected with PfSPZ Challenge (for CHMI).

    Biological: PfSPZ Challenge (for CHMI)

  • Experimental
    Group 2a (PfSPZ Vaccine)

    11-17 years; n=6; 3 doses of 9.0 x 10\^5 PfSPZ Vaccine given 8 weeks apart.

    Biological: PfSPZ Vaccine

  • Placebo comparator
    Group 2a (normal saline)

    11-17 years; n=3; 3 doses of normal saline given 8 weeks apart.

    Other: Normal Saline

  • Experimental
    Group 2b (PfSPZ Vaccine)

    11-17 years; n=6; 3 doses of 1.8 x 10\^6 PfSPZ Vaccine given 8 weeks apart.

    Biological: PfSPZ Vaccine

  • Placebo comparator
    Group 2b (normal saline)

    11-17 years; n=3; 3 doses of normal saline given 8 weeks apart.

    Other: Normal Saline

  • Experimental
    Group 3a (PfSPZ Vaccine)

    6-10 years; n=6; 3 doses of 9.0 x 10\^5 PfSPZ Vaccine given 8 weeks apart.

    Biological: PfSPZ Vaccine

  • Placebo comparator
    Group 3a (normal saline)

    6-10 years; n=3; 3 doses of normal saline given 8 weeks apart.

    Other: Normal Saline

  • Experimental
    Group 3b (PfSPZ Vaccine)

    6-10 years; n=6; 3 doses of 1.8 x 10\^6 PfSPZ Vaccine given 8 weeks apart.

    Biological: PfSPZ Vaccine

  • Placebo comparator
    Group 3b (normal saline)

    6-10 years; n=3; 3 doses of normal saline given 8 weeks apart.

    Other: Normal Saline

  • Experimental
    Group 4a (PfSPZ Vaccine)

    1-5 years; n=6; 3 doses of 4.5 x 10\^5 PfSPZ Vaccine given 8 weeks apart.

    Biological: PfSPZ Vaccine

  • Placebo comparator
    Group 4a (normal saline)

    1-5 years; n=3; 3 doses of normal saline given 8 weeks apart.

    Other: Normal Saline

  • Experimental
    Group 4b (PfSPZ Vaccine)

    1-5 years; n=6; 3 doses of 9.0 x 10\^5 PfSPZ Vaccine given 8 weeks apart.

    Biological: PfSPZ Vaccine

  • Placebo comparator
    Group 4b (normal saline)

    1-5 years; n=3; 3 doses of normal saline given 8 weeks apart.

    Other: Normal Saline

  • Experimental
    Group 5a (PfSPZ Vaccine)

    6-11 months; n=3; 1 dose of 2.7 x 10\^5 PfSPZ Vaccine.

    Biological: PfSPZ Vaccine

  • Experimental
    Group 5b (PfSPZ Vaccine)

    6-11 months; n=6; 3 doses of 4.5 x 10\^5 PfSPZ Vaccine given 8 weeks apart.

    Biological: PfSPZ Vaccine

  • Placebo comparator
    Group 5b (normal saline)

    6-11 months; n=3; 3 doses of normal saline given 8 weeks apart.

    Other: Normal Saline

  • Experimental
    Group 5c (PfSPZ Vaccine)

    6-11 months; n=6; 3 doses of 9.0 x 10\^5 PfSPZ Vaccine given 8 weeks apart.

    Biological: PfSPZ Vaccine

  • Placebo comparator
    Group 5c (normal saline)

    6-11 months; n=3; 3 doses of normal saline given 8 weeks apart.

    Other: Normal Saline

Interventions

  • BiologicalPfSPZ Vaccine

    Metabolically active, non-replicating, radiation attenuated, aseptic, purified, cryopreserved NF54 P. falciparum (Pf) sporozoites (PfSPZ Vaccine)

  • OtherNormal Saline

    0.9% Sodium chloride

  • BiologicalPfSPZ Challenge (for CHMI)

    live, infectious, aseptic, purified, cryopreserved NF54 P. falciparum (Pf) sporozoites (PfSPZ Challenge) Controlled human malaria infection (CHMI) by direct venous inoculation of 3,200 PfSPZ Challenge

06

What researchers measure

Primary outcomes

  1. Incidence and type of Adverse Events

    Incidence and type of adverse events (including breakthrough infections), vital signs, clinical laboratory assessments, physical examination findings post first immunization onwards. 1. Occurrence of solicited symptoms during a 7-day surveillance period after vaccination (day of vaccination (Vx) and +7 days post vaccination) 2. Occurrence of unsolicited symptoms during a 28-day surveillance period after each vaccination. 3. Occurrence of serious adverse events during the study period. 4. Occurrence of Pf infection of vaccine type detected at any point after the first vaccination (retrospectively determined).

    Time frame: Post first immunization uptil 56 days post-CHMI or 56 days post-3rd immunization

Secondary outcomes

  1. Level of Antibodies against Pf proteins in volunteer sera

    1. Antibody titres to pre-erythrocytic stage and erythrocytic stage antigens\[PfCSP, PfLSA-1, PfEBA-175 , PfMSP-1, PfMSP-5, EXP-1\] by ELISA 2. Antibody titres to Pf sporozoites, asexual and sexual erythrocytic stage parasites by IFA. 3. Analysis of antibodies to proteins in the Pf proteome array chip.

    Time frame: Post first immunization uptil 56 days post-CHMI or 56 days post-3rd immunization

  2. Inhibitory Capacity of Volunteer Sera against in vitro Sporozoite Invasion of Hepatocytes

    Capacity of sera from immunized volunteers to inhibit sporozoite invasion (ISI) of hepatocytes in vitro by ISI assay

    Time frame: Post first immunization uptil 56 days post-CHMI or 56 days post-3rd immunization

  3. Quantitation of cellular immune responses against Pf proteins in volunteers

    1. Identification of number of vaccine induced PBMCs following Intracellular cytokine staining by flow cytometry after stimulation with PfSPZ or Pf-infected erythrocytes, peptide pools and P. falciparum infected primary human hepatocyte cell lines. 2. Identification of numbers of vaccine induced CD4 and CD8 T cells following FluoroSpot assay after stimulation with PfSPZ or Pf-infected erythrocytes.

    Time frame: Post first immunization uptil 56 days post-CHMI or 56 days post-3rd immunization

  4. Whole genome expression profiles of volunteer

    Human gene expression profiling focusing on immune response genes in volunteers

    Time frame: Post first immunization uptil 56 days post-CHMI or 56 days post-3rd immunization

Other outcomes

  1. Number of adult volunteers protected against CHMI following immunization

    Evidence of vaccine-mediated protection against CHMI 3 weeks after last immunization in Groups 1 (adults) by preventing blood stage infection for 28 days (as detected by blood smear analysis and qPCR) following CHMI.

    Time frame: 28 days post CHMI

  2. Genetic profiles of Pf parasites

    Whole genome sequencing of Plasmodium falciparum following break through infections.

    Time frame: Screening uptil 56 days post-CHMI or 56 days post-3rd immunization

07

Study locations

1 site
  • Bagamoyo Research and Training center of the Ifakara Health Institute
    Bagamoyo, Tanzania
08

References and documents

Publications

  • Jongo SA, Church LWP, Mtoro AT, Schindler T, Chakravarty S, Ruben AJ, Swanson PA, Kassim KR, Mpina M, Tumbo AM, Milando FA, Qassim M, Juma OA, Bakari BM, Simon B, James ER, Abebe Y, Kc N, Saverino E, Fink M, Cosi G, Gondwe L, Studer F, Styers D, Seder RA, Schindler T, Billingsley PF, Daubenberger C, Sim BKL, Tanner M, Richie TL, Abdulla S, Hoffman SL. Increase of Dose Associated With Decrease in Protection Against Controlled Human Malaria Infection by PfSPZ Vaccine in Tanzanian Adults. Clin Infect Dis. 2020 Dec 31;71(11):2849-2857. doi: 10.1093/cid/ciz1152. PubMed 31782768 ↗
  • Schindler T, Jongo S, Studer F, Mpina M, Mwangoka G, Mswata S, Ramadhani K, Sax J, Church LWP, Richie TL, Tanner M, Hoffman SL, Abdulla S, Daubenberger C. Two cases of long-lasting, sub-microscopic Plasmodium malariae infections in adults from coastal Tanzania. Malar J. 2019 Apr 29;18(1):149. doi: 10.1186/s12936-019-2787-x. PubMed 31036014 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2015 to primary completion in Feb 2017, 14 months.

Of 29 industry-sponsored phase 1 interventional studies under Malaria, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 18. This study's 14 months is above that.

Counting every sponsor, half of 93 studies reached it within 13 months; a quarter within 7 and three quarters within 20.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2015
First posted
Nov 24, 2015
StartActual
Dec 2015
Primary completionActual
Feb 2017
CompletionActual
Mar 2017
Last update
Oct 15, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 15, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02613520
Lead sponsor
Sanaria Inc.
Collaborators
Ifakara Health Institute, Swiss Tropical & Public Health Institute, Medical Care Development, Inc., Tanzania Commission for Science and Technology, Government of Equatorial Guinea, Marathon Oil Corporation, Noble Oil Services
Responsible party
Sponsor
First posted
Nov 24, 2015
Start date
Dec 2015
Primary completion
Feb 2017
Completion
Mar 2017
Last update
Oct 15, 2018

Study contacts

Said Jongo, MD, MMED
principal investigator · Ifakara Health Institute (IHI), Bagamoyo, Tanzania

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion